Teva Pharmaceutical Industries Ltd (TEVA) - Total Liabilities
Based on the latest financial reports, Teva Pharmaceutical Industries Ltd (TEVA) has total liabilities worth ILA32.11 Billion ILA (≈ $86.10 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Teva Pharmaceutical Industries Ltd - Total Liabilities Trend (1985–2025)
This chart illustrates how Teva Pharmaceutical Industries Ltd's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Teva Pharmaceutical Industries Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.
Teva Pharmaceutical Industries Ltd Competitors by Total Liabilities
The table below lists competitors of Teva Pharmaceutical Industries Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Adriatic Metals Plc
F:3FN
|
Germany | €192.27 Million |
|
Wealthfront Corporation Common Stock
NASDAQ:WLTH
|
USA | $1.01 Billion |
|
IDT Corporation
NYSE:IDT
|
USA | $310.09 Million |
|
PT Daya Intiguna Yasa Tbk
JK:MDIY
|
Indonesia | Rp3.19 Trillion |
|
Manchester United Ltd
NYSE:MANU
|
USA | $2.07 Billion |
|
Growthpoint Properties Australia
AU:GOZ
|
Australia | AU$2.12 Billion |
|
Hangjin Technology Co Ltd
SHE:000818
|
China | CN¥5.18 Billion |
|
BioGaia AB (publ)
ST:BIOG-B
|
Sweden | Skr292.02 Million |
Liability Composition Analysis (1985–2025)
This chart breaks down Teva Pharmaceutical Industries Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Teva Pharmaceutical Industries Ltd (TEVA) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.79 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Teva Pharmaceutical Industries Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Teva Pharmaceutical Industries Ltd (1985–2025)
The table below shows the annual total liabilities of Teva Pharmaceutical Industries Ltd from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ILA32.84 Billion ≈ $88.05 Million |
-2.28% |
| 2024-12-31 | ILA33.61 Billion ≈ $90.10 Million |
-4.94% |
| 2023-12-31 | ILA35.35 Billion ≈ $94.78 Million |
+0.11% |
| 2022-12-31 | ILA35.31 Billion ≈ $94.68 Million |
-3.04% |
| 2021-12-31 | ILA36.42 Billion ≈ $97.65 Million |
-7.98% |
| 2020-12-31 | ILA39.58 Billion ≈ $106.11 Million |
-6.67% |
| 2019-12-31 | ILA42.41 Billion ≈ $113.69 Million |
-5.53% |
| 2018-12-31 | ILA44.89 Billion ≈ $120.35 Million |
-13.46% |
| 2017-12-31 | ILA51.87 Billion ≈ $139.06 Million |
-10.41% |
| 2016-12-31 | ILA57.90 Billion ≈ $155.22 Million |
+137.96% |
| 2015-12-31 | ILA24.33 Billion ≈ $65.23 Million |
+5.49% |
| 2014-12-31 | ILA23.07 Billion ≈ $61.84 Million |
-7.27% |
| 2013-12-31 | ILA24.87 Billion ≈ $66.68 Million |
-10.35% |
| 2012-12-31 | ILA27.74 Billion ≈ $74.38 Million |
-0.21% |
| 2011-12-31 | ILA27.80 Billion ≈ $74.53 Million |
+63.04% |
| 2010-12-31 | ILA17.05 Billion ≈ $45.71 Million |
+17.17% |
| 2009-12-31 | ILA14.55 Billion ≈ $39.01 Million |
-12.05% |
| 2008-12-31 | ILA16.54 Billion ≈ $44.35 Million |
+71.40% |
| 2007-12-31 | ILA9.65 Billion ≈ $25.88 Million |
+3.85% |
| 2006-12-31 | ILA9.29 Billion ≈ $24.92 Million |
+114.29% |
| 2005-12-31 | ILA4.34 Billion ≈ $11.63 Million |
+2.48% |
| 2004-12-31 | ILA4.23 Billion ≈ $11.35 Million |
+61.55% |
| 2003-12-31 | ILA2.62 Billion ≈ $7.02 Million |
-6.18% |
| 2002-12-31 | ILA2.79 Billion ≈ $7.49 Million |
+34.43% |
| 2001-12-31 | ILA2.08 Billion ≈ $5.57 Million |
+22.01% |
| 2000-12-31 | ILA1.70 Billion ≈ $4.56 Million |
+75.22% |
| 1999-12-31 | ILA971.72 Million ≈ $2.61 Million |
+25.16% |
| 1998-12-31 | ILA776.40 Million ≈ $2.08 Million |
+34.89% |
| 1997-12-31 | ILA575.60 Million ≈ $1.54 Million |
-18.49% |
| 1996-12-31 | ILA706.20 Million ≈ $1.89 Million |
+52.30% |
| 1995-12-31 | ILA463.70 Million ≈ $1.24 Million |
+39.00% |
| 1994-12-31 | ILA333.60 Million ≈ $894.37K |
+13.08% |
| 1993-12-31 | ILA295.00 Million ≈ $790.88K |
+32.94% |
| 1992-12-31 | ILA221.90 Million ≈ $594.91K |
+14.56% |
| 1991-12-31 | ILA193.70 Million ≈ $519.30K |
-6.96% |
| 1990-12-31 | ILA208.20 Million ≈ $558.18K |
+24.45% |
| 1989-12-31 | ILA167.30 Million ≈ $448.53K |
+12.28% |
| 1988-12-31 | ILA149.00 Million ≈ $399.46K |
+75.29% |
| 1986-12-31 | ILA85.00 Million ≈ $227.88K |
-4.71% |
| 1985-12-31 | ILA89.20 Million ≈ $239.14K |
-- |
About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-po… Read more